Leviticus Partners discloses 7.6% Harvard Bioscience (HBIO) stake in 13G/A

Rhea-AI Filing Summary

Harvard Bioscience investor Leviticus Partners reports beneficial ownership of 3,401,601 shares of common stock, representing 7.6% of the outstanding class as of December 31, 2025. The reporting person has sole power to vote and dispose of all these shares.

The stake is certified as being held in the ordinary course of business and not for the purpose of changing or influencing control of Harvard Bioscience, according to managing member Adam M. Hutt, who signed the Schedule 13G/A on behalf of the reporting person.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 6)

HARVARD BIOSCIENCE INC

(Name of Issuer)

Common Stock

(Title of Class of Securities)

416906105

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 416906105

1

Names of Reporting Persons

Leviticus Partners LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,401,601.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,401,601.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,401,601.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.6 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: HARVARD BIOSCIENCE INC
(b)	Address of issuer's principal executive offices: 84 OCTOBER HILL RD, 84 OCTOBER HILL RD, HOLLISTON, MASSACHUSETTS, 01746.
Item 2.
(a)	Name of person filing: Adam M Hutt
(b)	Address or principal business office or, if none, residence: 32 Old Mill Road Great Neck, NY 11023
(c)	Citizenship: United States
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 416906105
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 3,401,601
(b)	Percent of class: 7.6 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 3,401,601
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 3,401,601
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Leviticus Partners LP

Signature:	Adam M Hutt
Name/Title:	Managing Member
Date:	02/12/2026

FAQ

What ownership stake in Harvard Bioscience (HBIO) does Leviticus Partners report?

Leviticus Partners reports beneficial ownership of 3,401,601 Harvard Bioscience common shares, equal to 7.6% of the class as of December 31, 2025. This makes it a significant shareholder under SEC rules requiring Schedule 13G filings.

Does Leviticus Partners control voting and sale decisions for its HBIO shares?

Yes. The filing states Leviticus Partners has sole voting power and sole dispositive power over all 3,401,601 Harvard Bioscience shares. There is no shared voting or dispositive authority reported with any other party.

Why is Leviticus Partners filing a Schedule 13G/A on Harvard Bioscience (HBIO)?

The Schedule 13G/A is filed because Leviticus Partners beneficially owns more than 5% of HBIO common stock. The filing date of the reportable event is December 31, 2025, triggering the disclosure obligation under SEC beneficial ownership rules.

Is Leviticus Partners seeking to influence control of Harvard Bioscience (HBIO)?

According to the certification, the securities were acquired and are held in the ordinary course of business. The filer states they were not acquired, and are not held, to change or influence control of Harvard Bioscience or as part of a control-related transaction.

Who signed the Harvard Bioscience (HBIO) Schedule 13G/A for Leviticus Partners?

The Schedule 13G/A is signed by Adam M. Hutt, identified as a Managing Member. His address is listed as 32 Old Mill Road, Great Neck, NY 11023, and he certifies the information in the statement as true, complete, and correct.

What class of Harvard Bioscience (HBIO) securities is covered in this 13G/A?

The filing covers Harvard Bioscience Common Stock with CUSIP 416906105. Leviticus Partners’ reported 3,401,601 shares and 7.6% beneficial ownership relate specifically to this common stock class, not to any preferred shares or other securities.